Progress on ovine lentivirus and its resistant genes.
Hangzhou, China. In Yi Chuan, 20 Jan 2015
Here, we review the progress of E35K mutation in sheep TMEM154 gene and its effects on resistance to MVV, and other lentivirusresistant genes including zinc finger cluster, chemokine reveptor 5 (CCR5), tripartite motif-containing 5 alpha (TRIM5Α), apolipoprotein B mRNA-editing catalytic polypetide like 3 (APOBEC3), developmental pluripotencyassociated 2 (DPPA2) and DPPA4.
HIV-1 viral infectivity factor interacts with light chain 3 and inhibits autophagy.
Strasbourg, France. In Aids, 08 Jan 2015
Pull-down experiments, immunoprecipitation assays and computational analyses were performed to analyze the interaction between Vif and light chain 3B (LC3B), a major autophagy component, in presence or absence of the antiviral host factor apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), after HIV-1 infection or ectopic expression of Vif.
Hypermutation in human cancer genomes: footprints and mechanisms.
Durham, United States. In Nat Rev Cancer, 24 Dec 2014
This major expansion of cancer mutation data sets has provided unprecedented statistical power for the analysis of mutation spectra, which has confirmed several classical sources of mutation in cancer, highlighted new prominent mutation sources (such as apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) enzymes) and empowered the search for cancer drivers.
LOX-1 in atherosclerotic disease.
Matsumoto, Japan. In Clin Chim Acta, 22 Dec 2014
We hypothesized that LOX-1 is a candidate risk factor beyond LDL cholesterol (LDLC) and developed a novel assay to quantify LOX-1 ligand containing apoB (LAB).
ETC-1002: A future option for lipid disorders?
Palermo, Italy. In Atherosclerosis, 01 Dec 2014
The levels of apolipoprotein B (apoB) and non-high density lipoprotein cholesterol (non-HDL-C) were also reduced with beneficial effect on other cardiometabolic factors such as inflammatory markers, blood pressure and body weight.
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
More papers using
Amsterdam, Netherlands. In J Am Coll Cardiol, Sep 2014
OBJECTIVES: The aim of this meta-analysis was to evaluate: 1) the interindividual variability of reductions in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), or apolipoprotein B (apoB) levels achieved with statin therapy; 2) the proportion of patients not reaching guideline-recommended lipid levels on high-dose statin therapy; and 3) the association between very low levels of atherogenic lipoproteins achieved with statin therapy and cardiovascular disease risk.